FDA clears Plavix for additional heart indication

09/10/2006 | United Press International

The FDA has cleared Bristol-Myers Squibb's and Sanofi's Plavix anti-clotting drug for reducing the risk of fatal heart attack and the risk of a recurrent heart attack, stroke or death in patients with acute STEMI. Patients who have survived a STEMI incident, the most severe form of heart attack, are at higher risk of another heart attack, stroke or death.

View Full Article in:

United Press International

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA